LeMaitre Vascular stock
LMATNASDAQLeMaitre Vascular, Inc., HealthcareISIN US5255582018
70Score 70 out of 100, Strong
Price and trend
34 / 100
Price history
−14% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 18% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 38).
The price is 34% below its 52-week high. Largest decline in 20 years: 76% (November 2007 to December 2008).
Chart figures for advanced users
- SMA 50$81.36
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$94.26
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)38
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$77.65
- The lowest closing price of the last twelve months.
- Resistance$117.39
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- LeMaitre Vascular, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $1.78B, is number 37 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $249.6M (up 13.5% year on year) and earnings of $57.73M (up 31.1%).
- For fiscal 2026, analysts expect on average revenue of $276.27M (up 10.7%) and adjusted earnings per share of $2.84 (up 19.3%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 143 of 714 in Healthcare, median 53.
- The P/E is 28.3 (Medical (Instruments & Supplies) median 34.8, own median of recent years 39.5).
- Our model puts fair value at $84.46, with the price 6% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 19.4% a year since 2020.Growth 84
- Reliable dividendNo dividend cut for 15 years.Capital allocation 65
- High return on capitalReturn on invested capital 23.5% in fiscal 2025, Medical (Instruments & Supplies) median 5.4%.Profitability 89
Weaknesses
- DilutionShare count up 12% since 2020.Capital allocation 65
- Volatile share priceVolatility 46% a year over the last 12 months.
Its standout strengths are fundamentals and profitability, while technical analysis and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 71 to 70.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
- price far below its 52-week high
What lowers it
- solid fundamentals
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $60.33 and expensive above $140.77 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $73.48 (cash-flow model) and $95.45 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $78.15, at 7.8% it would be $93.95.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 11.8% on the twelve months before. Revenue has grown solidly since 2006, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 72%, operating 27%, net 23%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $0.65 (expected $0.69)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.84−1.2%
- Revenue
- $276.27M−0.1%
- Earnings per share
- $3.17−0.3%
- Revenue
- $303.83M+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −23.8%2026 revenue guidance lowered to $276.3 million, organic growth 11% instead of 12% and operating income $76.8 million; the stronger dollar, the Middle East war and supply limits weigh.
“We have updated our full year revenue guidance to $276.3 million and 11% reported revenue growth. Expected reported revenue has declined as we updated our FX assumptions for the strengthening U.S. dollar since our February and May guidance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- LeMaitre George WSale
8 May 2026, Chairman and CEO
- Shares
- 27,881
- Price
- $108.69
- Value
- $3.03M
- Kamke Trent GSale
8 May 2026, Senior V. P., Operations
- Shares
- 2,928
- Price
- $107.00
- Value
- $313,287
- LeMaitre George WSale
7 May 2026, Chairman and CEO
- Shares
- 18,600
- Price
- $107.64
- Value
- $2M
Show 5 more
- Ross Bridget ASale
7 May 2026, Board
- Shares
- 5,044
- Price
- $111.10
- Value
- $560,366
- Jasinski Lawrence JSale
7 May 2026, Board
- Shares
- 3,943
- Price
- $110.00
- Value
- $433,730
- Kamke Trent GSale
11 Mar 2026, Senior V. P., Operations
- Shares
- 2,625
- Price
- $108.50
- Value
- $284,813
- Roberts David BSale
11 Mar 2026, President and Director
- Shares
- 3,311.68
- Price
- $107.68
- Value
- $356,586
- LeMaitre George WSale
2 Mar 2026, Chairman and CEO
- Shares
- 55,930
- Price
- $107.81
- Value
- $6.03M
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at LeMaitre Vascular
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Bonesupport HoldingBONEX.ST $2.1B72
- DENTSPLY SIRONAXRAY $1.95B48
- Kestra Medical TechnologiesKMTS $1.88B45
- SKAN GroupSKAN.SW $1.88B72
- STAAR SurgicalSTAA $1.34B45
- GerresheimerGXI.DE $1.23B48
- Safilo GroupSFL.MI $952.24M61
- Dynavox GroupDYVOX.ST $784.94M66
ETFs that hold LeMaitre Vascular
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.11% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.08% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.22B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.19B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.